Herbet Mariola, Gawrońska-Grzywacz Monika, Izdebska Magdalena, Piątkowska-Chmiel Iwona, Jagiełło-Wójtowicz Ewa
Chair and Department of Toxicology, Medical University of Lublin, Lublin 20-093, Poland.
Exp Ther Med. 2016 Apr;11(4):1459-1464. doi: 10.3892/etm.2016.3068. Epub 2016 Feb 10.
Depression is among the most prevalent and life-threatening forms of mental illness, and is also a risk factor for cardiovascular disorders, diabetes and metabolic syndrome. Elderly patients commonly receive statins for the prevention of cardiovascular diseases, and antidepressant drugs for the treatment of depression. It should be noted that long-term polypharmacotherapy may lead to potential drug interactions and disorders of the organs. The aim of the present study was to determine whether, and to what extent, combined treatment with rosuvastatin and antidepressants (amitriptyline or fluoxetine) influences the biochemical markers of liver and kidney function in a rat model. For this purpose, the activity levels of aspartate aminotransferase, alanine aminotransferase (ALT), γ-glutamyltransferase (GGT) and the concentrations of total protein, urea, creatinine and β-microglobulin were determined. The results of the study indicated that combined treatment with rosuvastatin and the antidepressants amitriptyline and fluoxetine for 14 days altered the activity levels of ALT and GGT, and the concentrations of urea and creatinine in the serum compared with groups of rats receiving rosuvastatin or either antidepressant alone. These observed changes in biochemical parameters may suggest the possibility of impaired liver and kidney function during the continuous combined exposure to the drugs. However, further clinical and animal studies are required in order to further elucidate this process.
抑郁症是最常见且危及生命的精神疾病形式之一，也是心血管疾病、糖尿病和代谢综合征的危险因素。老年患者通常会服用他汀类药物来预防心血管疾病，并服用抗抑郁药物来治疗抑郁症。应当注意的是，长期联合用药可能会导致潜在的药物相互作用以及器官功能紊乱。本研究的目的是确定瑞舒伐他汀与抗抑郁药（阿米替林或氟西汀）联合治疗是否以及在何种程度上会影响大鼠模型中肝脏和肾脏功能的生化指标。为此，测定了天冬氨酸转氨酶、丙氨酸转氨酶（ALT）、γ-谷氨酰转移酶（GGT）的活性水平以及总蛋白、尿素、肌酐和β-微球蛋白的浓度。研究结果表明，与单独接受瑞舒伐他汀或任何一种抗抑郁药治疗的大鼠组相比，瑞舒伐他汀与抗抑郁药阿米替林和氟西汀联合治疗14天会改变血清中ALT和GGT的活性水平以及尿素和肌酐的浓度。这些观察到的生化参数变化可能表明在持续联合用药期间肝脏和肾脏功能受损的可能性。然而，需要进一步的临床和动物研究来进一步阐明这一过程。
